Source: International Congress 2014 – Clinical trials in IPF
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
U. Costabel, Y. Inoue, L. Richeldi, H. R. Collard, S. Stowasser, I. Tschoepe, A. Azuma (Essen, Ingelheim am Rhein, Germany; Osaka, Tokyo, Japan; Southampton, United Kingdom; San Francisco, United States Of America; Reims, France). Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials. Eur Respir J 2014; 44: Suppl. 58, 1907

Member's Comments

No comment yet.

Related content which might interest you: Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Sensitivity analyses from the INPULSIS™ trials of nintedanib Source: International Congress 2014 – Clinical trials in IPF Year: 2014 6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations Source: International Congress 2014 – ILDs 6 Year: 2014 Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO Source: International Congress 2014 – ILDs 6 Year: 2014 Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP) Source: International Congress 2014 – IPF and surroundings Year: 2014 Clinical data, lung function and cardiopulmonary exercise testing in CPFE (combined pulmonary fibrosis with emphysema). Results of a cohort of 20 patients Source: International Congress 2014 – ILDs 6 Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Comparison of physiological impairment in ILD patients with and without diagnostic IPF features Source: International Congress 2014 – ILDs 4 Year: 2014 Lung 18F-FDG uptake correlates with lung function alteration in patients with IPF Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Annual changes in pulmonary function are independent prognostic factors for the patients with chronic hypersensitivity pneumonia Source: International Congress 2014 – ILDs 3 Year: 2014 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014